Targeting myeloid-derived suppressor cells for cancer immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting myeloid-derived suppressor cells for cancer immunotherapy

Published:2018-05-31 Issue:8 Volume:67 Page:1181-1195
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Liu Yijun,Wei Guowei,Cheng Wesley A.,Dong Zhenyuan,Sun Han,Lee Vincent Y.,Cha Soung-Chul,Smith D. Lynne,Kwak Larry W.,Qin Hong

Funder

U.S. Department of Defense

Leukemia and Lymphoma Society

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-018-2175-3/fulltext.html

Reference152 articles.

1. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174. https://doi.org/10.1038/nri2506

2. Choi HS, Ha SY, Kim HM, Ahn SM, Kang MS, Kim KM, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Kang ES (2016) The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. Oncotarget 7(7):7940–7951. https://doi.org/10.18632/oncotarget.6958

3. Chevalier MF, Trabanelli S, Racle J, Salome B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, Dartiguenave F, Fritschi AS, Speiser DE, Rentsch CA, Gfeller D, Jichlinski P, Nardelli-Haefliger D, Jandus C, Derre L (2017) ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest 127(8):2916–2929. https://doi.org/10.1172/JCI89717

4. Youn JI, Gabrilovich DI (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40(11):2969–2975. https://doi.org/10.1002/eji.201040895

5. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22(4):275–281. https://doi.org/10.1016/j.semcancer.2012.01.011

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activating CD8⁺ T Cells by Pt(IV) Prodrug‐Based Nanomedicine and aPD‐L1 Antibody for Enhanced Cancer Immunotherapy;Advanced Materials;2024-02-23

2. Deacetylase sirtuin 2 negatively regulates myeloid-derived suppressor cell functions in allograft rejection;American Journal of Transplantation;2023-12

3. Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy;Acta Pharmaceutica Sinica B;2023-11

4. Evaluation of the anti-tumor effects of an anti-Human Epidermal growth factor receptor 2 (HER2) monoclonal antibody in combination with CD11b+/Gr-1+ myeloid cells depletion using a recombinant peptibody in 4 T1-HER2 tumor model;International Immunopharmacology;2023-08

5. MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target;Frontiers in Immunology;2023-07-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3